We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 16, 2022

Longitudinal Stability of the JCV Antibody Index in Individuals With MS Treated With Natalizumab

Multiple Sclerosis and Related Disorders


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis and Related Disorders
Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis
Mult Scler Relat Disord 2022 Dec 01;68(xx)104251, M Gaughan, M Gilligan, I Patterson, I McGurgan, SM Yap, N Tubridy, C McGuigan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading